MacroGenics Inc.

10/26/2026 | Press release | Distributed by Public on 10/26/2026 05:15

MacroGenics Announces Positive Interim Phase 2 LINNET Results for Lorigerlimab in Advanced Clear Cell Gynecologic Cancer Single agent lorigerlimab demonstrated encouraging[...]

Read this content
Click here to read the original version at the source's official website. The text of this article is not available at the moment.
MacroGenics Inc. published this content on October 26, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on October 26, 2026 at 11:15 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]